{"public_id":"cl_dc65e207b29518898a580f535e2567bb","status":"active","superseded_by_public_id":null,"corpus_id":207577951,"text":"No new safety signals were observed and the safety profile was consistent with the known profile of pirfenidone.","confidence":0.99,"paper":{"corpus_id":207577951,"title":"An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)","url":"https://sah.borca.ai/papers/207577951"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.99,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_09efc98f2274b71be61e0eab17900867","name":"safety signal","description":"A newly detected or unexpected potential safety concern arising from clinical data.","types":["safety assessment"],"url":"https://sah.borca.ai/concepts/co_09efc98f2274b71be61e0eab17900867"},{"public_id":"co_3fcf86768265b02a3ec265fa6dd7d35d","name":"safety profile","description":"The overall pattern of adverse events and tolerability associated with a treatment.","types":["outcome","safety assessment"],"url":"https://sah.borca.ai/concepts/co_3fcf86768265b02a3ec265fa6dd7d35d"},{"public_id":"co_7409daee74d4701ab4dfd47abdcc218f","name":"pirfenidone","description":"An antifibrotic drug evaluated here for long-term safety in idiopathic pulmonary fibrosis.","types":["drug","treatment"],"url":"https://sah.borca.ai/concepts/co_7409daee74d4701ab4dfd47abdcc218f"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_dc65e207b29518898a580f535e2567bb"}